ISRCTN52253218已完成3 期
A Phase III randomised comparison of Gemcitabine/Carboplatin with Mitomycin, Ifosfamide and Cisplatin in non-small cell lung cancer
ondon Lung Cancer Group (UK)0 个研究点目标入组 422 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 422
研究概览
简要总结
2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15625369 results
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically proven non-small cell carcinoma of the lung
- •2. Stage IIIb or IV disease
- •3. Measurable or evaluable disease
- •4. Adequate renal function (Ethylene diamine tetraacetic acid [EDTA] Clearance >60 ml/min)
- •5. Age 18 or over
- •6. Adequate contraception in females of child-bearing potential
- •7. Written informed consent
- •8. No prior radiotherapy or chemotherapy
- •9. Not less than 8 weeks life expectancy
- •10. No history of prior malignancy (except non-melanomatous skin tumour or has been without evidence of disease for 3 years or more)
- •11. White cell count >3000/ml Platelet count >100,000/ml Haemaglobin >10.0 g.dL
- •12. No symptomatic brain metastases
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
3 期
A Phase III Randomised comparison of Gemcitabine/Carboplatin with Cisplatin/Etoposide in Small Cell Lung Cancerung (small cell) cancerLung (small cell)CancerISRCTN39679215CRI CSG and London Lung Cancer Group (UK)241
已完成
3 期
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary SiteNeoplasms, Unknown PrimaryNCT00193596SCRI Development Innovations, LLC198
已完成
2 期
Randomized phase II study comparing Gemcitabine chemoradiotherapy with Gemcitabine chemotherapy for unresectable locally advanced pancreatic cancer.nresectable locally advanced pancreatic cancer.JPRN-UMIN000012253Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology110
招募中
不适用
Gemzar studyCancerPACTR201510001143243AMPATH Oncology Institute70
进行中（未招募）
1 期
A Phase III Randomized Trial of Gemcitabine plus Docetaxel followed by Doxorubicin v. observation for uterus-limited, High Grade Uterine LeiomyosarcomaPatients with high risk uterine LMS, FIGO stage I (confined to corpus +/-cervix).MedDRA version: 18.1Level: PTClassification code 10046799Term: Uterine leiomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-002852-17-DKEORTC216